Page last updated: 2024-10-26

dipyridamole and Telangiectasis

dipyridamole has been researched along with Telangiectasis in 1 studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Telangiectasis: Permanent dilation of preexisting blood vessels (CAPILLARIES; ARTERIOLES; VENULES) creating small focal red lesions, most commonly in the skin or mucous membranes. It is characterized by the prominence of skin blood vessels, such as vascular spiders.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Requena, L1
FariƱa, C1
Barat, A1

Other Studies

1 other study available for dipyridamole and Telangiectasis

ArticleYear
Degos disease in a patient with acquired immunodeficiency syndrome.
    Journal of the American Academy of Dermatology, 1998, Volume: 38, Issue:5 Pt 2

    Topics: Acquired Immunodeficiency Syndrome; Atrophy; Cicatrix; Dipyridamole; Erythema; Homosexuality, Male;

1998